Genfleet Therapeutics Secures Hundreds of Millions in Series B+ Financing, Xingyuan Capital Acts as Exclusive Financial Advisor

GenFleet Therapeutics recently announced the completion of its hundreds-of-millions-yuan Series B+ financing round, led by Northern Light Venture Capital. Participating investors included HM CAPITAL, Linden Asset Group, and Shanghai Shanjin Asset Management Co., Ltd., along with existing shareholders such as CDH Investments and Panlin Capital. Yuanxing Zhitong served as the exclusive financial advisor for this transaction. As GenFleet enters a new stage of global multi-center clinical trials, the proceeds from this round will be used to accelerate the R&D and clinical trial processes of the company’s existing products, build an internationally advanced R&D system, and simultaneously initiate industrialization layouts, continuously achieving milestone breakthroughs in the development of “global-first” innovative drugs.

Dr. Lv Qiang, Chairman of GenFleet Therapeutics, stated: “We extend our gratitude to Northern Light Venture Capital and other new and existing investors for their recognition of and confidence in GenFleet’s performance and prospects. The company has now entered a new phase of development characterized by global multi-center clinical trials. This year, multiple clinical studies are expected to be launched across China, the United States, and Australia, while our industrialization strategy is also advancing steadily. GenFleet will continue to focus on disease biological mechanisms and translational clinical medicine to build a pipeline of first-in-class global innovations, thereby driving industry advancement and benefiting patients worldwide.”

Dr. Lan Jiong, CEO of GenFleet Therapeutics, stated: “Since receiving angel investment from HuiMei Capital and other investors in 2017, GenFleet has made leapfrog strides in its portfolio, expanding from small-molecule drug pipelines to a diverse array of cutting-edge therapies. We remain committed to building a ‘global-first’ drug development system, focusing primarily on innovative targets and corresponding indications that lack clinical validation, while simultaneously establishing a large-scale platform with multiple parallel development models. Leveraging our profound scientific expertise and robust project execution capabilities, GenFleet aims to forge a globally innovative drug R&D engine and develop a product portfolio that is leading in China, at the international forefront, and advanced and well-balanced.”

Deng Feng, Founding Managing Partner of Northern Light Venture CapitalIt was pointed out that Dr. Lü Qiang and Dr. Lan Jiong are veterans in the innovative drug industry. The team boasts extensive experience in drug molecule design and drug development, has built a highly promising product pipeline, and has achieved rapid clinical progress. This represents not only a breakthrough in China’s innovative drug sector but also a boon for numerous patients. We look forward to the company’s continued launch of medicines that benefit patients.

Dr. Song Gaoguang, Partner at Northern Light Venture Capital and Newly Appointed Member of the Board of Directors of GenFleet TherapeuticsStatement: GenFleet Therapeutics boasts a robust product portfolio, with multiple products holding leading positions both domestically and internationally. Several of its candidates have already entered clinical trials. The company’s team possesses extensive experience in new drug development and demonstrates high operational efficiency. We look forward to the company’s timely completion of product development to provide patients with superior treatment options.

Fu Jia, Managing Director of Xingyuan ZhitongStatement: It is a great honor to assist GenFleet Therapeutics in completing its Series B+ financing round. Centered on the biological mechanisms of oncology and immunology and their clinical translation, GenFleet Therapeutics focuses on addressing unmet clinical needs in multiple fields, including cancer and autoimmune diseases. In less than four years since its establishment, the company has advanced multiple drug candidates into clinical stages, demonstrating the team’s sustained R&D capabilities and exceptional execution. We wish GenFleet Therapeutics continued breakthroughs in its business endeavors, bringing benefits to patients worldwide.

Founded by Mr. Deng Feng in 2005, Northern Light Venture Capital is committed to “empowering world-class Chinese entrepreneurs and cultivating world-class Chinese enterprises.” The firm has long focused on investing in early-stage, technology-driven innovative companies, and to date has invested in nearly 400 outstanding enterprises across the TMT, advanced technology, and healthcare sectors.

Northern Light Venture Capital entered the healthcare sector in 2009. Over the past decade, it has invested across multiple sub-sectors—including medical devices, in vitro diagnostics (IVD), biopharmaceuticals, healthcare services, and E-Health—covering nearly the entire industry value chain. The firm has invested in more than 60 companies, such as CITIC Pharmaceutical, BGI Genomics, Burning Rock Biotech, Zeltis Pharma, iRay Technology, Taimei Medical Technology, Cytek Biosciences, Guoke Hengtai, Conatus Pharmaceuticals, Conviction Therapeutics, and Yidao Bio.
About GenFleet TherapeuticsGenFleet Therapeutics is driven by unmet clinical needs, with a core focus on disease biology and translational medicine. The company conducts in-depth research into the latest biological mechanisms in areas such as tumor signaling pathways, the tumor immune microenvironment, and immunomodulation. It prioritizes the development of innovative targets and indications that lack prior clinical validation, dedicating itself to the creation of original, first-in-class global novel drugs with independent global intellectual property rights.

Over the three years since its establishment, GenFleet Therapeutics has built a comprehensive technology platform, R&D system, and talent pipeline covering both large- and small-molecule drugs. Its product portfolio includes more than ten “global first-in-class” projects, with multiple candidate drugs having entered global clinical development stages. Notably, the company’s first independently developed transforming growth factor-beta receptor 1 (TGF-β R1) inhibitor is poised to enter Phase II clinical trials, showing broad clinical application prospects in the treatment of solid tumors such as liver cancer and urothelial carcinoma. The company’s second investigational new drug, a cyclin-dependent kinase 9 (CDK9) inhibitor, has also received clinical trial approvals in both China and the United States, marking the launch of its first global multicenter clinical study. Over the next three to five years, as more R&D projects advance into late-stage clinical trials, the company is expected to enter the industrialization phase.